Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 15, Issue 4, 2014, Pages 410-418

  Sharma, Ashish Kumar ^a   Kanawat, Devendra Singh ^a   Mishra, Akanksha ^a   Dhakad, Prashant Kumar ^a   Sharma, Prashant ^a   Srivastava, Varnika ^a   Joshi, Sneha ^a   Joshi, Megha ^a   Raikwar, Sachin Kumar ^a   Kurmi, Muneem Kumar ^a   Srinivasan, Bharthu Parthsarthi ^b  

^a SURESH GYAN VIHAR UNIVERSITY   (India)

^b DELHI INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

Author keywords

Diabetic nephropathy; renin angiotensin system (RAS); telmisartan add on vildagliptin; type 2 diabetes mellitus

Indexed keywords

ALBUMIN; CREATININE; GLIMEPIRIDE; GLUCOSE; METFORMIN; NICOTINAMIDE; PIOGLITAZONE; STREPTOZOCIN; TELMISARTAN; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; GLUCOSE BLOOD LEVEL; NITRILE; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HISTOPATHOLOGY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINARY EXCRETION; ALBUMINURIA; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BLOOD PRESSURE; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIASTOLE; DIET RESTRICTION; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; SYSTOLE; WISTAR RAT;

ADAMANTANE; ALBUMINURIA; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; BLOOD PRESSURE; BLOOD UREA NITROGEN; BODY WEIGHT; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIASTOLE; DRUG THERAPY, COMBINATION; FASTING; HYPOGLYCEMIC AGENTS; MALE; NITRILES; PYRROLIDINES; RATS, WISTAR; SYSTOLE;

EID: 84918493547     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320313475908     Document Type: Article

References (14)

1. Gross JL, deAzevedo MJ, Silveiro SP, et al. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care. 2005 ; 28: 164-176
2. Berkman J, Harold R. Unilateral nodular diabetic glomerulosclerosis (Kimmelstiel-Wilson): Report of a case. Metabolism. 1973 ; 22: 715-722
3. Vildagliptin, http://en.wikipedia.org/wiki/Vildagliptin (2012, accessed 21 February 2012).
4. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension. 2004 ; 43: 993-1002
5. Sharma AM, Weir MR. The role of angiotensin receptor blockers in diabetic nephropathy. Postgrad Med. 2011 ; 123: 109-121
6. Sharma AK, Srinivasan BP. Triple verses glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats. Eur J Pharm Sci. 2009 ; 38: 433-444
7. Sharma AK, Sharma A, Kumari R, et al. Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats. J Biomed Res. 2012 ; 26: 200-210
8. Rao RP, Jain AK, Srinivasan BP. Dual therapy versus monotherapy of trandolapril and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats. J Renin Angiotensin Aldosterone Syst. 2011 ; 12: 169-175
9. Rao RP, Singh A, Jain AK, et al. Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats. J Biomed Res. 2011 ; 25: 411-417
10. Fukami K. Agents in development for the treatment of diabetic nephropathy. Expert Opin Investig Drugs. 2005 ; 14: 279-294
11. Singh J, Budhiraja S, Lal H, et al. Renoprotection by telmisartan versus benazepril in streptozotocin induced diabetic nephropathy. Iranian J Pharmacol Therap. 2006 ; 5: 135-139
12. Sasser JM, Sullivan JC, Hobbs JL, et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol. 2007 ; 18: 143-154
13. Chen LL, Zang JY, Wang BP. Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. Vascul Pharmacol. 2006 ; 44: 309-315
14. Okada T, Wada J, Hida K, et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes. 2006 ; 55: 1666-1677